Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1354
Shown on this page
12
Current sort
Recently updated
Campus scope
Stanford Medicine, Stanford & Palo Alto, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Stanford Medicine, Stanford & Palo Alto, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 421–432 of 1,354 matching trials with a site at Stanford Medicine, Stanford & Palo Alto, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

NCT06646627
Status at this site: Recruiting
View directory record Official record
Conditions
Ovarian Cancer
Interventions
B7-H3CART
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

NCT05438212
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
208
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

NCT05119296
Site status not listed — check the official record
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Saad A Khan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

NCT07447557
Status at this site: Recruiting
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease Type 4J
Interventions
ELP-02
Genetic
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
3 Years to 20 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Phase 2 Interventional

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

NCT06745076
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Vinblastine, Questionnaire
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
6
States / cities
Irvine, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting No phase listed Observational

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038
Site status not listed — check the official record
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Osimertinib, Osimertinib + Chemotherapy
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
146
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Phase 2 Interventional

Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

NCT07594431
Status at this site: Recruiting
View directory record Official record
Conditions
Metastases, Metastatic Cancer
Interventions
LATTICE Radiotherapy, Standard radiotherapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Active, not recruiting Not applicable Interventional

PRIMARY Ancillary Substudy

NCT07103733
Site status not listed — check the official record
View directory record Official record
Conditions
Mitral Valve Prolapse, Left Ventricular Fibrosis, Ventricular Arrhythmias
Interventions
Cardiac Magnetic Resonance Imaging, ZioPatch Monitoring, Myocardial Tissue Biopsy
Procedure · Device
Lead sponsor
Annetine Gelijns
Other
Eligibility
60 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
TNG462, Pembrolizumab
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 2:01 AM EDT
Not yet recruiting Not applicable Interventional

Single Arm Intervention Trial of DEKA TWIIST TM Insulin Pump Utilizing Tidepool Loop Algorithm in Pregnant People With Pre-existing Type 1 Diabetes

NCT07808385
Site status not listed — check the official record
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy
Interventions
Automated Insulin Delivery (AID)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 2:01 AM EDT

About this Stanford Medicine institution page

What this page lists
ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.